207 related articles for article (PubMed ID: 32133215)
1. Development of microRNA-based therapy for pancreatic cancer.
Fesler A; Ju J
J Pancreatol; 2019 Dec; 2(4):147-151. PubMed ID: 32133215
[TBL] [Abstract][Full Text] [Related]
2. microRNA based prognostic biomarkers in pancreatic Cancer.
Guo S; Fesler A; Wang H; Ju J
Biomark Res; 2018; 6():18. PubMed ID: 29942514
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.
Xiong J; Wang D; Wei A; Ke N; Wang Y; Tang J; He S; Hu W; Liu X
Oncotarget; 2017 Dec; 8(64):107500-107512. PubMed ID: 29296182
[TBL] [Abstract][Full Text] [Related]
4. The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma.
Ren L; Yu Y
Ther Clin Risk Manag; 2018; 14():179-187. PubMed ID: 29416345
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
[TBL] [Abstract][Full Text] [Related]
6. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma.
Guo S; Fesler A; Huang W; Wang Y; Yang J; Wang X; Zheng Y; Hwang GR; Wang H; Ju J
Mol Ther Nucleic Acids; 2020 Mar; 19():228-239. PubMed ID: 31846800
[TBL] [Abstract][Full Text] [Related]
7. microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer.
Funamizu N; Honjo M; Tamura K; Sakamoto K; Ogawa K; Takada Y
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831572
[TBL] [Abstract][Full Text] [Related]
8. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
10. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview.
Quiñonero F; Mesas C; Doello K; Cabeza L; Perazzoli G; Jimenez-Luna C; Rama AR; Melguizo C; Prados J
Cancer Biol Med; 2019 Nov; 16(4):688-699. PubMed ID: 31908888
[TBL] [Abstract][Full Text] [Related]
11. Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy.
Passadouro M; Faneca H
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187371
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
[TBL] [Abstract][Full Text] [Related]
13. Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma.
Hu X; Chen W
World J Clin Cases; 2021 Jul; 9(19):4998-5006. PubMed ID: 34307550
[TBL] [Abstract][Full Text] [Related]
14. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.
Garajová I; Le Large TY; Giovannetti E; Kazemier G; Biasco G; Peters GJ
Methods Mol Biol; 2016; 1395():163-87. PubMed ID: 26910074
[TBL] [Abstract][Full Text] [Related]
15. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside.
Uddin MH; Al-Hallak MN; Philip PA; Mohammad RM; Viola N; Wagner KU; Azmi AS
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204940
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.
Hernandez YG; Lucas AL
World J Gastrointest Oncol; 2016 Jan; 8(1):18-29. PubMed ID: 26798434
[TBL] [Abstract][Full Text] [Related]
17. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
Steele CW; Oien KA; McKay CJ; Jamieson NB
Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic Cancer Chemoresistance to Gemcitabine.
Amrutkar M; Gladhaug IP
Cancers (Basel); 2017 Nov; 9(11):. PubMed ID: 29144412
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
20. miRNAs in pancreatic cancer progression and metastasis.
Mok ETY; Chitty JL; Cox TR
Clin Exp Metastasis; 2024 Jan; ():. PubMed ID: 38240887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
